X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Rapid Cutback of Intracranial Pressure By Injectable Peptide

    Tumors Can Get Destroyed By Bacteria-Aid To Immune System

    Tumors Can Get Destroyed By Bacteria-Aid To Immune System

    Default Eligibility Results In Better Clinical Trial Nods

    Researchers Develop Revolutionary Treatment In Bone Cancer

    Singapore Precision Drugs To Excel By Next-Gen Proteomics

    Temperature Stable TB Vaccine Gives Out Immune Response

    T Cells Are Fruitful In Thwarting-Off Chronic Infections

    Randomness Drives Tumour Cells Response To Chemotherapy

    mAbs And Therapeutic Proteins Potency Guidance Issued By FDA

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Rapid Cutback of Intracranial Pressure By Injectable Peptide

    Tumors Can Get Destroyed By Bacteria-Aid To Immune System

    Tumors Can Get Destroyed By Bacteria-Aid To Immune System

    Default Eligibility Results In Better Clinical Trial Nods

    Researchers Develop Revolutionary Treatment In Bone Cancer

    Singapore Precision Drugs To Excel By Next-Gen Proteomics

    Temperature Stable TB Vaccine Gives Out Immune Response

    T Cells Are Fruitful In Thwarting-Off Chronic Infections

    Randomness Drives Tumour Cells Response To Chemotherapy

    mAbs And Therapeutic Proteins Potency Guidance Issued By FDA

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Featured

Indian Pharma Business May Increase 8-11%, Predicts Alkem

Content Team by Content Team
13th July 2022
in Featured, Manufacturing, News
Indian Pharma Business May Increase 8-11%, Predicts Alkem

When the epidemic subsides, Alkem Laboratories predicts that inflationary pressures and shifting regulatory standards will be the primary concerns to keep an eye on, and that normal business operations would allow the Indian pharmaceutical industry to resume its 8–11% growth pace.

The future of the domestic pharmaceutical market, according to Alkem’s annual report for 2021–2022, continues to hold enormous potential, driven by favourable demographics, rising spending power, enhanced access to healthcare services, rising awareness of healthcare, and rising penetration of medical insurance.

Regarding the outlook for domestic business, it was stated that the Indian pharmaceutical sector is predicted to bounce back to a standardised growth rate of 8–11% with the relaxation of COVID-19 restrictions, the resumption of travel, the regularisation of supply chain and manufacturing activities, the reopening of schools and offices, and the reinstatement of deferred elective medical treatments.

The company said that worldwide COVID-19-related closures and quarantines resulted in postponing elective medical procedures and individuals being less involved in their healthcare, delaying diagnosis and treatment, particularly for illnesses that were asymptomatic.

The main concerns to be aware of, according to Alkem, are inflationary pressures such as rising prices for packaging and raw materials; increasing freight rates; and changing regulatory standards.

Alkem, which continues to have a favourable outlook on the Indian pharmaceutical industry, claimed that its dominance in the acute section with market-leading mega brands, a sizable field force, and a prevalent supply chain and distribution system puts it on a firm footing in the domestic market.

The business is expanding at a quick clip to become a key participant in the chronic market. Biosimilars should keep contributing to its growth and cover portfolio gaps with their regular product introductions. Alkem stated that the adoption of new medicines and sub-therapies would be another significant growth driver in the future.

Regarding the viewpoint for the US market, which is the largest pharmaceutical market in the world, Alkem stated that despite difficulties with pricing, fierce competition, and stricter regulatory compliance requirements, it is optimistic about its growth prospects there, prompted by new product introductions and USFDA-compliant manufacturing facilities. With a balanced mix of Para IV and first-to-file (FTF) possibilities, it has a strong pipeline of over 160 abbreviated new medication applications submitted to the USFDA, which offers it significant visibility of growth over the medium term.

Alkem stated that it intends to eventually use its subsidiary Enzene Biosciences to introduce biosimilars to the US market. In order to expand its expertise and product range and gain market share in the US pharmaceutical industry, it would also proactively consider in-licensing options, collaborations, and partnerships.

Previous Post

DoKaSch Temperature Solutions and Japan Airlines sign Master Rental Agreement

Next Post

FDA Clears Novavax COVID-19 Vaccine As Fourth Option In US

Related Posts

Drug Development

Rapid Cutback of Intracranial Pressure By Injectable Peptide

16th March 2023
Tumors Can Get Destroyed By Bacteria-Aid To Immune System
News

Tumors Can Get Destroyed By Bacteria-Aid To Immune System

16th March 2023
News

Default Eligibility Results In Better Clinical Trial Nods

10th March 2023
News

Researchers Develop Revolutionary Treatment In Bone Cancer

10th March 2023
Drug Development

Singapore Precision Drugs To Excel By Next-Gen Proteomics

10th March 2023
Clinical Trials

Temperature Stable TB Vaccine Gives Out Immune Response

10th March 2023
Next Post
Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

FDA Clears Novavax COVID-19 Vaccine As Fourth Option In US

Latest News

Drug Development

Rapid Cutback of Intracranial Pressure By Injectable Peptide

16th March 2023
Tumors Can Get Destroyed By Bacteria-Aid To Immune System
News

Tumors Can Get Destroyed By Bacteria-Aid To Immune System

16th March 2023
News

Default Eligibility Results In Better Clinical Trial Nods

10th March 2023
News

Researchers Develop Revolutionary Treatment In Bone Cancer

10th March 2023
Drug Development

Singapore Precision Drugs To Excel By Next-Gen Proteomics

10th March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In